Global GLP-1 Agonist Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global GLP-1 Agonist Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
GLP-1 is a polypeptide hormone secreted by the intestine after being stimulated by food. It can stimulate the pancreatic beta cells to secrete insulin and participate in the regulation of blood sugar balance in the human body. However, natural GLP-1 is easily degraded by dipeptidyl peptidase in vivo and loses its activity. In order to make GLP-1 better for clinical application, drug developers have modified its structure and developed a series of GLP-1 receptor agonists. GLP-1 receptor agonists can exert the same biological effects as natural GLP-1, and can also avoid being degraded and inactivated, thereby prolonging the action time.
GLP-1 Agonist report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global GLP-1 Agonist market is projected to reach US$ 44730 million in 2034, increasing from US$ 20600 million in 2022, with the CAGR of 16.6% during the period of 2024 to 2034. Demand from Diabetes and Obesity are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for GLP-1 Agonist industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, GLP-1 Agonist key manufacturers include Novo Nordisk, AstraZeneca, Sanofi, GSK, Eli Lilly, Zealand Pharma A/S, hansoh and BENEMAE, etc. Novo Nordisk, AstraZeneca, Sanofi are top 3 players and held % sales share in total in 2022.
GLP-1 Agonist can be divided into Long-Acting Drug and Short-Acting Drug, etc. Long-Acting Drug is the mainstream product in the market, accounting for % sales share globally in 2022.
GLP-1 Agonist is widely used in various fields, such as Diabetes, Obesity, Nonalcoholic Fatty Liver Disease and Metabolic Disorder, etc. Diabetes provides greatest supports to the GLP-1 Agonist industry development. In 2022, global % sales of GLP-1 Agonist went into Diabetes filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global GLP-1 Agonist market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Novo Nordisk
AstraZeneca
Sanofi
GSK
Eli Lilly
Zealand Pharma A/S
hansoh
BENEMAE
Segment by Type
Long-Acting Drug
Short-Acting Drug
Diabetes
Obesity
Nonalcoholic Fatty Liver Disease
Metabolic Disorder
Alzheimer's Disease
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the GLP-1 Agonist market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of GLP-1 Agonist, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the GLP-1 Agonist industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of GLP-1 Agonist in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, GLP-1 Agonist introduction, etc. GLP-1 Agonist Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of GLP-1 Agonist market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
GLP-1 Agonist report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global GLP-1 Agonist market is projected to reach US$ 44730 million in 2034, increasing from US$ 20600 million in 2022, with the CAGR of 16.6% during the period of 2024 to 2034. Demand from Diabetes and Obesity are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for GLP-1 Agonist industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, GLP-1 Agonist key manufacturers include Novo Nordisk, AstraZeneca, Sanofi, GSK, Eli Lilly, Zealand Pharma A/S, hansoh and BENEMAE, etc. Novo Nordisk, AstraZeneca, Sanofi are top 3 players and held % sales share in total in 2022.
GLP-1 Agonist can be divided into Long-Acting Drug and Short-Acting Drug, etc. Long-Acting Drug is the mainstream product in the market, accounting for % sales share globally in 2022.
GLP-1 Agonist is widely used in various fields, such as Diabetes, Obesity, Nonalcoholic Fatty Liver Disease and Metabolic Disorder, etc. Diabetes provides greatest supports to the GLP-1 Agonist industry development. In 2022, global % sales of GLP-1 Agonist went into Diabetes filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global GLP-1 Agonist market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novo Nordisk
AstraZeneca
Sanofi
GSK
Eli Lilly
Zealand Pharma A/S
hansoh
BENEMAE
Segment by Type
Long-Acting Drug
Short-Acting Drug
Segment by Application
Diabetes
Obesity
Nonalcoholic Fatty Liver Disease
Metabolic Disorder
Alzheimer's Disease
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the GLP-1 Agonist market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of GLP-1 Agonist, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the GLP-1 Agonist industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of GLP-1 Agonist in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, GLP-1 Agonist introduction, etc. GLP-1 Agonist Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of GLP-1 Agonist market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices